Effect of agomelatine on first-episode depression and its influence on cognitive function
- VernacularTitle:阿戈美拉汀治疗首发抑郁症患者的疗效及对认知功能的影响
- Author:
Song GENG
1
;
Zhongxia SHEN
Author Information
1. 浙江省湖州市第三人民医院心身障碍科
- Keywords:
First-episode depression;
Agomelatine;
Paroxetine hydrochloride;
Cognitive function
- From:
China Modern Doctor
2018;56(15):114-116,120
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of agomelatine in treating first-episode depression and its influnce on cognitive function. Methods 100 patients with first-episode depression who were admitted in our hospital from January 2015 to January 2017 were selected as study subjects and randomly divided into observation group and control group with 50 cases in each group according to different treatment methods. The control group was treated with paroxetine hydrochloride and the observation group was given agomelatine. After treatment, the clinical efficacy between the two groups was evaluated. At the same time, the scores of visual space and executive, naming, memory, attention, language, abstraction, delay memory and orientation in the cognitive function between two groups before and after treatment were compared. Results After treatment, the clinical efficacy of the two groups was evaluated. The results showed that the total effective rate in the observation group and that in the control group was 88. 0％ and 80. 0％ after treatment. There was no significant difference in the total efficiency between the two groups(P＞0. 05). Before treatment, there was no significant difference between the two groups in cognitive function in terms of visual space and executive, naming, memory, attention, language, abstraction, delayed memory, and directional score. After treatment, visual space and executive, naming, memory, attention, language, abstraction, delayed memory and directed score in cognitive function in two groups were significantly higher than those before treatment. And the scores of cognitive function in the observation group were significantly higher than those in the control group. There was significant difference between the groups P＜0. 05). Conclusion Agomelatine has significant clinical efficacy in the treatment of patients with first-episode depression and can improve the cognitive function of patients and improve the quality of life of patients, which is worthy of widely clinical application.
